Experimental therapies for multiple sclerosis: current status.
Multiple sclerosis is the most common cause of nontraumatic disability affecting young adults in the United States. Its etiology remains unclear, but evidence points to alteration of normal immune system function in the pathogenesis of this illness. This article reviews the results of clinical trials of experimental therapeutic agents in multiple sclerosis. The background and action of each treatment are described, and the clinical experience with each agent is reviewed. Obstacles to evaluating the effectiveness of treatment methods in MS and challenges to the design of future clinical trials and the interpretation of trial outcomes are discussed.
Goodkin
D E
DE
Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, OH 44195.
Ransohoff
R M
RM
Rudick
R A
RA
D001379:Azathioprine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D003524:Cyclosporins / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D015182:Lymphatic Irradiation; D008297:Male; D009103:Multiple Sclerosis / Q000628:therapy*; D010455:Peptides / Q000627:therapeutic use; D010956:Plasmapheresis; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology
D003524:Cyclosporins; D010455:Peptides; C021759:(T,G)-A-L; D003520:Cyclophosphamide; D007372:Interferons; D001379:Azathioprine